Full Press Release Details
RESEARCH TRIANGLE PARK, NC -- (MARKET WIRE) -- January 9, 2007 --SCYNEXIS, Inc. today announced
that it has earned a $1 million payment from Merck & Co., Inc. for meeting
certain preclinical milestones in the companies' collaboration to develop
novel antifungal agents.
"Merck and SCYNEXIS have collaborated for several years to discover and
develop novel antifungal agents," said Merv Turner, Ph.D., Merck senior
vice president, Worldwide Licensing and External Research. "We are pleased
with the progress we've made to date and with SCYNEXIS' contributions to
"SCYNEXIS is pleased to celebrate the success in reaching an important
milestone in this project with our valued partner Merck," noted Yves
Ribeill, Ph.D., President and Chief Executive Officer of SCYNEXIS. "This
milestone was achieved through a true and open partnership."
SCYNEXIS is a chemistry-focused drug discovery and development company with
its headquarters located in Research Triangle Park, North Carolina.
SCYNEXS' goal, from concept to clinic, is to deliver effective and
innovative drug pipeline solutions to our pharmaceutical partners.
SCYNEXIS' research teams integrate computational chemistry, medicinal
chemistry, bioanalysis and process chemistry. SCYNEXIS teams use powerful,
proprietary technologies such as the HEOS Software Suite,
MEDCHEM-FACTORY and KIT Kinase Inhibitor Technology to optimize lead
molecules for candidate selection. SCYNEXIS process chemistry and
bioanalytical departments operate under current GMP/GLP guidelines and have
established a strong track record of success. SCYNEXIS tailors its teams
to be especially effective in moving customer projects from the discovery
phase to clinical proof of concept. SCYNEXIS' website is located at
Contact Information: CONTACTS:
SCYNEXIS Media Contact:
Rick Rountree Communications
SCYNEXIS Market Development Contact: